CurrentEmpire BluecrossPolicy 04-302

Local Delivery of Antimicrobial Agents

This policy governs use of subgingival local delivery chemotherapeutic/antimicrobial agents as adjunctive therapy for refractory periodontal pockets and during periodontal maintenance for Empire Bluecross members; it is intended for dentists and reviewers determining dental necessity and benefit coverage.

Policy Summary

PayerEmpire Bluecross

PolicyLocal Delivery of Antimicrobial Agents

Policy CodePolicy 04-302

Change TypeNo material change

Effective DateJan 1, 2023

Next Review DateN/A

Key ActionProvide a current (within 12 months) dated 6-point periodontal charting when requesting local delivery antimicrobial therapy for a refractory site.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

>=5 mmpocket depth threshold

6 wks–6 moshealing interval

12 mocharting recency

D4381primary CDT code

Coverage Criteria for Local Delivery of Antimicrobial Agents (LDCA)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

inv-01: Indications for LDCA

Covered when ALL of the following are met

Primary criteria: 1) Definitive non-surgical (scaling and root planing) and/or surgical periodontal treatment has been completed for the site; 2) The target site is a refractory or active periodontal site defined as a pocket >= 5 mm with persistent signs of inflammation (spontaneous bleeding or bleeding on probing), suppuration, increasing pocket depth and/or increasing clinical attachment loss; 3) Adequate healing time has elapsed (6 weeks to 6 months post scaling and root planing or periodontal surgery); 4) A current (within 12 months) 6-point periodontal charting is provided; and 5) Only teeth with favorable periodontal outcomes will be considered for benefit.pocket >= 5 mm

LDCA may also be indicated as adjunct during periodontal maintenance for localized recurrent/residual inflamed sites.

inv-02: Contraindications / Not Appropriate Uses

Not appropriate when ANY of the following are present

Exclusion criteria: 1) Periodontal probing depths less than 5 mm; 2) Generalized periodontitis where a more comprehensive intervention or surgical therapy is indicated; 3) Use of LDCA for regeneration of alveolar bone (considered experimental/investigational); 4) Multiple recurrent sites requiring more extensive periodontal surgical modalities rather than local adjunctive therapy.

Services performed in conjunction with non-covered services may also be denied.

Coding and Clinical Thresholds

CDT Codes (informational)CDT

D4381	Localized delivery of antimicrobial agents via a controlled release vehicle into diseased crevicular tissue per tooth
D4341	Periodontal scaling and root planing, four or more teeth per quadrant
D4342	Periodontal scaling and root planing, one to three teeth per quadrant
D4346	Scaling in the presence of generalized moderate or severe gingival inflammation full mouth, after oral exam
D4910	Periodontal maintenance
D4999	Unspecified periodontal procedure; by report
D6081	Scaling and debridement in the presence of inflammation or mucositis of a single implant, including cleaning of the implant surfaces, without flap entry and closure

Pocket depth threshold — clinical threshold for LDCA eligibility

Clinical pocket depth threshold>= 5 millimeters

Context for thresholdApplies to active/refractory periodontal sites considered for LDCA

Timing relative to prior therapyPerformed after adequate healing (6 weeks to 6 months post scaling and root planing or periodontal surgery)

Provider Action Items, Documentation & Billing

Billing Rule

Coding and benefit verification

Use CDT D4381 for billing localized delivery of antimicrobial agents. Verify member contract benefits and prior authorization requirements before performing or billing for LDCA.

CDT: D4381

Note

Adjunct after initial therapy

LDCA (local delivery of chemotherapeutic/antimicrobial agents) is appropriate only as an adjunctive therapy after definitive non-surgical therapy (scaling and root planing) or as adjunct to periodontal maintenance for localized recurrent/residual inflamed sites. Allow adequate healing time — LDCA may be performed 6 weeks to 6 months after scaling and root planing or periodontal surgery.

Adjunct to: scaling and root planing (D4341, D4342)
Adjunct to: periodontal maintenance (D4910)
Timing: 6 weeks to 6 months post-therapy

Documentation Required

Required periodontal charting

A current (within 12 months), dated 6-point periodontal charting is required and must be included in the record for post-maintenance and/or post-surgical sites when submitting for LDCA. Charting should document probing depths, bleeding on probing, suppuration, and changes in attachment level for the treated sites.

Periodontal charting: 6-point, dated, within 12 months
Document: pocket depths, bleeding on probing, suppuration, attachment changes
Applicable when: post-periodontal maintenance or post-periodontal surgery

Denial Risk

Improper indication or non-covered related services

LDCA is not appropriate for periodontal probing depths < 5 mm. When services are performed in conjunction with a non-covered or denied service, related services may also be denied. Denial risk exists for LDCA provided without objective evidence of refractory or recurrent sites (e.g., pockets ≥ 5 mm with signs of inflammation) or for billing related inappropriate services.

Contraindication: probing depths < 5 mm (not appropriate)
Denial risk: services for sites < 5 mm or lacking documentation of refractory disease
Plan note: related services performed with non-covered/denied services may be denied

Key Definitions

Active/refractory site — definition

DefinitionA periodontal pocket 5 millimeters or greater that shows signs of inflammation, spontaneous bleeding or bleeding on probing, suppuration, increasing pocket depth and/or increasing attachment loss

Typical useDescribes an active or refractory site that may be considered for localized delivery of antimicrobial agents (LDCA)

Adjunctive roleLDCA may be indicated at these sites as an adjunct to periodontal maintenance when localized recurrent/residual inflammation is present

Contraindication — LDCA not appropriate for probing depths < 5 mm; generalized periodontitis may need comprehensive therapy

Primary contraindicationLDCA modalities are not appropriate for periodontal probing depths less than 5 mm

Generalized diseaseWhen a generalized pattern of periodontitis is diagnosed, more comprehensive interventions or surgical therapies should be considered

When multiple recurrent sites presentMultiple recurrent and/or residual inflamed sites after scaling/root planing typically require more extensive periodontal therapeutic modalities (e.g., surgical procedures)